| Filed On | Filing |
|---|---|
| 21 Oct 2026 | ARS |
| 19 Oct 2026 |
Proxy statement: annual meeting on December 1, 2026
say-on-pay vote |
| 13 Oct 2026 | SCHEDULE 13G/A |
| 08 Oct 2026 | PRE 14A |
| 01 Oct 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
On September 25, 2026, Lantern Pharma Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with Nasdaq’s Listing Rule 5550(b)(2), as the market value of lis... |
| 30 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
This Securities Purchase Agreement (this “Agreement”) is dated as of September 28, 2026, between Lantern Pharma Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including it... |
| 30 Sep 2026 | 424B5 |
| 24 Sep 2026 |
8-K: Regulation FD Disclosure
On September 23, 2026, Lantern Pharma Inc. (the “Company”) hosted a live webinar to discuss the Open-Medicine AI multi-agentic AI platform for drug development. |
| 23 Sep 2026 |
8-K: Regulation FD Disclosure
Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET |
| 14 Aug 2026 | 10-Q |
| 14 Aug 2026 | 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure |
| 04 Aug 2026 | SCHEDULE 13G |
| 03 Aug 2026 | 8-K: Regulation FD Disclosure |
| 23 Jul 2026 | SCHEDULE 13G/A |
| 18 Jun 2026 | EFFECT |
| 12 Jun 2026 | S-1 |
| 02 Jun 2026 | 8-K: Regulation FD Disclosure |
| 21 May 2026 | D |
| 15 May 2026 | SCHEDULE 13D/A |
| 15 May 2026 | 8-K: Results of Operations and Financial Condition |
Loading...
